Clinical Trial

Testing Experimental HIV Medication in Healthy Subjects

Study Description

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 BG505 SOSIP.664 gp140 with TLR agonist and/or alum adjuvants in healthy, HIV-uninfected adults.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - BG505 SOSIP.664 gp140

Administered by IM injection

Biological - Placebo

Administered by IM injection

Biological - 3M-052-AF

Administered by IM injection

Biological - CpG 1018

Administered by IM injection

Biological - GLA-LSQ

Administered by IM injection

Biological - Alum (Aluminum Hydroxide Suspension)

Administered by IM injection

Additional Information

Official Study Title

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Clinical Trial ID

NCT04177355

ParticipAid ID

eER3Na